GSK3B and early-onset autosomal dominant Alzheimer disease: The aim of this study is to enhance the therapeutic potential of astaxanthin (AST) in Alzheimer’s disease by formulating it into invasomal carriers, with special emphasis on SIRT-1/BDNF/miRNA-134/GSK-3β signaling in an AD-like rat model caused by aluminum chloride (AlCl3) at a dose of 100 mg/kg/day for 60 days.